Related Experiment Video
Updated: Nov 30, 2025
14:33
Morphometric Analyses of Retinal Sections
Published on: February 19, 2012
10.6K
Potential neuroprotective biomolecules in ophthalmology
Mehrdad Afarid1, Fatemeh Sanie-Jahromi2
1Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Zand Boulevard, Poostchi Street, Shiraz, Iran.
International Ophthalmology
|November 12, 2020
Summary
Neuroprotective agents show promise for managing retinal neurodegenerative diseases like glaucoma and diabetic retinopathy. Classification of these agents aids in selecting optimal treatments, but clinical trials are essential for efficacy validation.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Retinal neurodegenerative diseases cause significant global vision impairment.
- Early intervention with neuroprotective molecules is key to managing disease progression.
Purpose of the Study:
- To review common neuroprotective bioagents investigated for ophthalmic conditions.
- To categorize these agents based on their therapeutic mechanisms.
Main Methods:
- Literature search of Web of Science, PubMed, and Scopus databases.
- Keywords included specific retinal diseases and neuroprotection.
Main Results:
- Identified commonly used neuroprotective drugs in ophthalmology.
- Classified agents into three categories: neurotrophins, intraocular pressure reducers, and apoptosis inhibitors.
Conclusions:
- A wide array of neuroprotective drugs exist for neuro-ophthalmic diseases.
- Drug classification can assist specialists in treatment selection.
- Further controlled clinical trials are necessary to validate treatment efficacy.
